uses JavaScript to provide the best possible experience for our content, but your browser has it disabled. Learn how to enable it here.


Posted July 4, 2017

FDA Warns Against Company's Unsafe Teething Tablets

On June 20, 2017, the FDA issued a warning letter to Raritan Pharmaceuticals, Inc. following a routine inspection of the facility when it found the company's Homeopathic Infant's Teething Tablets in violation of current good manufacturing practice (CGMP) regulations.

The teething tablets contain inconsistent amounts belladonna alkaloids, which the FDA believes to represent a serious health hazard to children and have unpredictable effects.

Additionally, statements made about Homeopathic Infant's Teething Tablets such as "Natural relief of pain & irritability from teething," "Temporarily relieves the symptoms of simple restlessness and wakeful irritability due to cutting teeth," and "Helps reduce gum redness and pain" were found to be drug claims.

See related recalls and warnings:

Hyland's Baby Teething Tablets and Nighttime Teething Tablets Recalled

FDA Testing Confirms Elevated Levels of Belladonna in Some Homeopathic Teething Products

Homeopathic Teething Tablets and Ear Relief Products Containing Belladonna Recalled

Homeopathic Teething Tablets and Gels May Pose Danger, FDA Warns

To read the FDA's warning letter, use the link below.